Adalta Ltd has released a press release.
New AD-214 data de-risks clinical studies
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from AdAlta
- AD-214 clinical trial approval
- AdAlta to present at June 1 Virtual Investor Summit
- AdAlta secures A$1.28 million in rights offer to advance AD-214
- Rights Offer results
- AdAlta to support early return to clinical trials of AD-214 with rights offer
Later from AdAlta
- $1.87 million raised in oversubscribed Shortfall facility
- AD-214 returns to clinic
- AdAlta to Present at August 24th Virtual Investor Summit
- AD-214 Phase I extension study fully enrolled
- Dosing simulations support AD-214 IV product profile
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta